Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE Maria Abreu, MD

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

News All Time

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Two medications might work better for breast cancers that are resistant to one.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.

3.

Some low-grade prostate cancers carry higher risks than biopsy suggests

4.

Even a few mutated cells can significantly impact how blood cancers develop, study finds

5.

Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes

1.

Risk Assessment of Functional Vulnerability During Long-Term Cancer Survivorship

2.

Preventing Cancer-Associated Cachexia Through Early Muscle Proteolysis Signature Monitoring

3.

Unlocking the Potential of Polatuzumab for Cancer Treatment

4.

The Importance of Having a Quick and Effective Heparin Antidote

5.

Unlocking the Potential of Etoposide: A Novel Approach to Cancer Treatment

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

2.

Cancer Care: From Awareness to Recovery

3.

Innovations in Hematology

4.

Innovations in Hematology

5.

How Nutrition Can Support Patients During Cancer Care

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Latest News

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE Maria Abreu, MD

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

News All Time

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Recommended News For You

Ibrutinib Fails in High-Risk Early-Stage CLL

Early Results for Anorexia Nervosa with Psilocybin.

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live

Could AI plus lasers help catch very early breast cancers?

Integrative palliative care is critical to improving mental health among pancreatic cancer patients

Two medications might work better for breast cancers that are resistant to one.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

Recommended Articles For You

AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance

Screening for Occult Platelet Dysfunction: Mechanisms, Clinical Implications, and Evidence-Based Approaches

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment

Exploring Innovative Solutions for Infantile Hemangioma Treatment

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.